Hongbo Lu

This profile gathers the share dealings of Hongbo Lu across 3 companies, led by Zenas BioPharma, Inc., Arrowhead Pharmaceuticals, Inc. and Terns Pharmaceuticals, Inc. In total, 13 filings cover trades dated from 12 August 2022 to 12 May 2026.

The open-market side counts 10 purchases for €16.1M alongside 1 sale for €195k. The net balance comes to €15.9M on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants. So far in 2026, the count stands at 3 purchases and 1 sale.

A typical purchase (the median) is worth €1.1M. 6 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -4.6%. These figures describe past trades and do not predict future prices.

Most recently, on 14 May 2026, the filings show an open-market sale worth €195k in Arrowhead Pharmaceuticals, Inc. The most recent open-market purchase was published on 2 April 2026, 199 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.